HSV hides in nerve cells where today’s medicines can’t reach it. Scientists are now testing gene editing, long-acting antivirals and new vaccines. We follow that work in plain language, with sources, and raise money to help push it forward.
Todavía no hay ningún ensayo de curación reclutando. Únete ahora para recibir novedades y enterarte antes que nadie cuando se abra uno.
The most-watched HSV candidates, placed on the path every new treatment has to travel. Updated October 25, 2026.
| Candidate | Lab & animalPhase 1Phase 2Phase 3FDA reviewApproved |
Latest status |
|---|---|---|
HSV gene therapyFred Hutch Cancer Center (Jerome & Aubert labs)Cure |
Preclinical. Removed 90%+ of latent HSV‑1 in mice and cut recurrences in guinea pigs; preparing for a first human trial. Leer el resumen | |
PritelivirAiCurisAntiviral |
FDA priority review, decision expected Q4 2026. For hard-to-treat HSV in people with weakened immune systems. Leer el resumen | |
ABI‑5366 / ABI‑1179Assembly Bio, licensed to GileadLong-acting antiviral |
Phase 1b complete: 94% fewer shedding days vs placebo for ABI‑5366. Gilead leads Phase 2 planning. Leer el resumen | |
mRNA‑1608ModernaTherapeutic vaccine |
Phase 1/2 in people with recurrent genital herpes completed; results posted May 2026. Leer el resumen | |
BNT163BioNTech with University of PennsylvaniaPreventive vaccine |
Phase 1 enrolment complete; trial active, not recruiting. Source |
Position shows the furthest stage reached, not the chance of success. Most candidates that enter Phase 1 never reach approval.
After infection, HSV goes quiet inside clusters of nerve cells called ganglia, then periodically wakes up. Every research strategy is an answer to that one problem.
Aim: cure
Gene-editing enzymes are delivered to the nerve cells where HSV sleeps and cut its DNA so it can’t repair itself. In animals this has removed most of the hidden virus. It is the only approach aimed at eliminating HSV, and it is still preclinical.
Aim: near-total control
New drug classes such as helicase-primase inhibitors block a different step of viral copying than acyclovir. Long-acting versions could mean a weekly or monthly pill, with far less shedding and fewer outbreaks.
Aim: prevent and suppress
Preventive vaccines try to stop infection in the first place. Therapeutic vaccines try to help people who already have HSV keep it suppressed. mRNA has given this field a second wind after earlier failures.
Each update is a plain-language summary of a published study, trial result or regulatory decision, with the original source.
The scientist leading the best-known HSV gene-therapy program sat down to talk cure research. Here’s the background that makes the conversation worth your time.
Leer el resumen
Results from the Phase 1/2 study of mRNA‑1608 in adults with recurrent genital herpes are now public. Here’s what the trial was designed to answer.
Leer el resumen
Assembly Bio completed follow-up for its two helicase-primase inhibitors. The headline number: 94% fewer days of viral shedding than placebo.
Leer el resumenRecaudación comunitaria
The gap between a promising animal study and a first human trial is where good science most often stalls. Safety studies, manufacturing and regulatory work are expensive, and they are rarely the kind of work big funders rush to pay for.
In animal studies, the leading gene-therapy approach removed over 90% of the hidden herpes virus. The next step is proving it is safe for people.
Funds raised are used to support HSV cure research. We publish exactly where each donation goes in our updates.
Fondos destinados a: Investigación para curar el VHS
Donar en GoFundMeCompletarás tu donación de forma segura en GoFundMe. GoFundMe puede mostrar una propina opcional; no es obligatoria y no va a la investigación.
Straight answers, including the ones that are less exciting.
No. As of October 2026 there is no approved treatment that removes HSV from the body. Current antivirals like valacyclovir reduce outbreaks and transmission but don’t touch the virus hiding in nerve cells.
Honestly, not soon. The leading cure approach, gene editing, is still preparing for its first human trial. If it works, approval would likely take many years after that. Better suppressive drugs could arrive much sooner.
We don’t run trials. When a researcher or sponsor starts recruiting for an HSV trial, we email the people on our list the trial’s public details and how to apply. Until then, you get our research updates. We never share your name or email with researchers or sponsors.
Some HSV trials do recruit. Search “herpes simplex” on ClinicalTrials.gov, filter for “Recruiting”, and talk to your doctor before enrolling.
Funds raised are used to support HSV cure research. We publish exactly where each donation goes in our updates.
No. We summarise published research for a general audience. For diagnosis or treatment, please speak with a qualified healthcare professional.
Never. Every email has a one-click unsubscribe link. Read the privacy policy.
Resultados de ensayos, aprobaciones y avances, explicados con claridad la misma semana en que ocurren. Sin compromiso de voluntariado.
Tu nombre y tu correo. Nada más.